Scholarlink

<p>Big data collected in large international cooperations allow validation of findings from traditional national patient cohorts for proving consistency. In this study we analyzed outcomes and phenotypic features of <i>TP53</i>-mutated chronic myelomonocytic leukemia (CMML) patients in the Austrian biodatabase for CMML (ABCMML; <i>n</i> = 322) and in the international platform cBIOPORTAL (<i>n</i> = 399). The prevalences of <i>TP53</i> mutations were 1.58 and 3.66, respectively. Numerically, overall survival was shorter in <i>TP53</i>-mutated patients in both cohorts (ABCMML 10.0 vs. 30.0 months and cBIOPORTAL 8.9 vs. 34.5 months), but this was statistically significant only in the cBIOPORTAL cohort. Decreased hemoglobin values and the presence of blast cells in peripheral blood were significantly associated with <i>TP53</i> mutations in the cBIOPORTAL group but not in the ABCMML database. Our study indicates the necessity of sufficient patient numbers for the comparison of CMML patients regarding outcome and phenotype according to their molecular subtype, particularly in the case of rare mutations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Features of TP53-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and international cohort (cBIOPORTAL)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月5日

查看全文
  • Magdalena Grass,
  • Klaus Geissler

摘要

Big data collected in large international cooperations allow validation of findings from traditional national patient cohorts for proving consistency. In this study we analyzed outcomes and phenotypic features of TP53-mutated chronic myelomonocytic leukemia (CMML) patients in the Austrian biodatabase for CMML (ABCMML; n = 322) and in the international platform cBIOPORTAL (n = 399). The prevalences of TP53 mutations were 1.58 and 3.66, respectively. Numerically, overall survival was shorter in TP53-mutated patients in both cohorts (ABCMML 10.0 vs. 30.0 months and cBIOPORTAL 8.9 vs. 34.5 months), but this was statistically significant only in the cBIOPORTAL cohort. Decreased hemoglobin values and the presence of blast cells in peripheral blood were significantly associated with TP53 mutations in the cBIOPORTAL group but not in the ABCMML database. Our study indicates the necessity of sufficient patient numbers for the comparison of CMML patients regarding outcome and phenotype according to their molecular subtype, particularly in the case of rare mutations.